| 摘要 |
Disclosed are N-((2-oxo-1,2-dihydropyridin-3-yl)methyl)-biphenyl-3-carboxamide derivatives of Formula (I) or a pharmaceutically acceptable salt thereof: wherein X1 is N or CR11; X2 is N or CR13; Z is NR7R8, OR7, S(O)nR7, or CR7R8R14; each of R1, R5, R9, and R10, independently, is H or optionally substituted alkyl; each of R2, R3, and R4 is independently H, or a substituent as defined herein; R6 is aryl or heteroaryl, each of which is optionally substituted; each of R8, R11, R12, and R13, independently is H, or a substituent; and wherein the remaining substituents are as defined herein. Representative compounds include 5-(cyclopentyl(methyl)amino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4’-((dimethylamino)methyl)-4-methyl-[1,1’-biphenyl]-3-carboxamide, 5-(cyclopentyl(methyl)amino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4-methyl-4’-(morpholinomethyl)-[1,1’-biphenyl]-3-carboxamide, 2-(cyclohex-1-en-1-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-((dimethylamino)methyl)phenyl)isonicotinamide, N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-(4-((dimethylamino)methyl)phenyl)-6-(piperidin-1-yl)isonicotinamide, N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-3-((tetrahydropyran-4-yI)(methyl)amino)-5-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)benzamide and 5-(tetrahydropyran-4-yI(ethyl)amino)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-4’-((morpholin-4-yl)methyl)-4-methyl-[1,1’-biphenyl]-3-carboxamide. Also disclosed is a pharmaceutical composition comprising a compound as defined above or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, for treating cancer, such as lymphoma, leukaemia, melanoma, prostate cancer, breast cancer, non-Hodgkin lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. |
